LA JOLLA PHARMACEUTICAL CO Form 8-K November 06, 2003 Table of Contents

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

# FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2003

# LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6455 Nancy Ridge Drive San Diego, California 92121 (Address of Principal Executive Offices, Including Zip Code)

Registrant s telephone number, including area code: (858)452-6600

### TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition. SIGNATURES EXHIBIT 99.1

#### **Table of Contents**

#### Item 12. Results of Operations and Financial Condition.

On November 6, 2003, La Jolla Pharmaceutical Company issued a press release announcing the financial results for its third fiscal quarter ended September 30, 2003. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Form 8-K and the exhibit attached hereto and incorporated herein shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

#### Table of Contents

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2003

#### LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Steven B. Engle

Steven B. Engle Chairman of the Board and Chief Executive Officer

## Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

#### Table of Contents

#### EXHIBIT INDEX

Exhibit Number

Description of Exhibit

99.1

Press Release (furnished pursuant to Item 12 of Form 8-K)